Implantable sensor devices, systems, and methods

Patent metadata

Field	Value
Publication number	US-12502108-B2
Application number	US-202318205297-A
Country	US
Kind code	B2
Filing date	Jun 2, 2023
Priority date	Jun 29, 2012
Publication date	Dec 23, 2025
Grant date	Dec 23, 2025

Abstract

Disclosed herein are devices, systems, and methods for a continuous analyte sensor, such as a continuous glucose sensor. In certain embodiments disclosed herein, various in vivo properties of the sensor's surroundings can be measured. In some embodiments, the measured properties can be used to identify a physiological response or condition in the body. This information can then be used by a patient, doctor, or system to respond appropriately to the identified condition.

First claim

What is claimed is:

1 . A method for processing data, the method comprising:
receiving sensor data generated by a glucose sensor, wherein the sensor data is indicative of a concentration of glucose in a host; identifying, using a processor, a post-implantation loss of sensitivity of the glucose sensor by measuring a plurality of time-varying concentration values of a non-glucose analyte and determining if at least one of the plurality of time-varying concentration values of the non-glucose analyte changes more than a predetermined amount; releasing a bio-active agent configured to minimize reduction or cessation of blood flow to a site surrounding sensor implantation based on the identification of the post-implantation loss of sensitivity; and processing the sensor data, using the processor, responsive to the identification of the post-implantation loss of sensitivity.

2 . The method of claim 1 , wherein the sensor data comprises data indicative of a signal response to at least one event selected from the group consisting of a signal response to cessation of blood flow to a site surrounding sensor implantation, a signal response to reduction of blood flow to a site surrounding sensor implantation, and a signal response to a vasospastic event.

3 . The method of claim 1 , wherein identifying the post-implantation loss of sensitivity comprises determining a severity of the loss of sensitivity.

4 . The method of claim 3 , wherein processing the sensor data is performed based on the severity of the loss of sensitivity.

5 . The method of claim 1 , wherein identifying the post-implantation loss of sensitivity comprises:
deactivating the glucose sensor for a time period, whereby a product from a catalyzed reaction of glucose and oxygen accumulates over the time period; activating the glucose sensor and measuring a signal value of the glucose sensor immediately after the time period.

6 . The method of claim 1 , wherein the non-glucose analyte is oxygen and the plurality of time-varying concentration values are oxygen levels or correlated to oxygen transport.

7 . The method of claim 1 , wherein the glucose sensor comprises a first electrode and a second electrode.

8 . The method of claim 7 , wherein the first electrode and the second electrode have different dimensions.

9 . The method of claim 8 , wherein the second electrode is configured to have a dimension that positions the second electrode post-implantation outside of a site affected by cessation or reduction of blood flow.

10 . The method of claim 9 , wherein at least one of the first electrode and the second electrode is configured to minimize tissue trauma from implantation.

11 . The method of claim 7 , further comprising:
determining that the second electrode is positioned outside of a site affected by cessation or reduction of blood flow; and wherein processing the sensor data responsive to the identification of the loss of sensitivity comprises according more weight to sensor data generated by the second electrode than sensor data generated by the first electrode.

12 . The method of claim 1 , wherein the post-implantation loss of sensitivity is transient.

13 . The method of claim 1 , wherein the post-implantation loss of sensitivity of the glucose sensor is due to a local cessation of blood flow in an implantation area.

14 . A system for detecting glucose comprising:
a sensor configured to be inserted within a host, the sensor configured to generate sensor data indicative of a concentration of glucose in the host; sensor electronics in communication with the sensor, wherein the sensor electronics include at least one processor configured to:
identify a post-implantation loss of sensitivity of the sensor by measuring a plurality of time-varying concentration values of a non-glucose analyte and determine if at least one of the plurality of time-varying concentration values of the non-glucose analyte changes more than a predetermined amount,
release a bio-active agent configured to minimize reduction or cessation of blood flow to a site surrounding sensor implantation based on the identifying of the post-implantation loss of sensitivity, and
process the sensor data responsive to the identification of the post-implantation loss of sensitivity; and
a display in communication with the sensor electronics, wherein the display is configured to display information about the concentration of glucose in the host.

15 . The system of claim 14 , wherein the sensor comprises a first electrode and a second electrode, wherein the first electrode has different dimensions than the second electrode.

16 . The system of claim 15 , wherein the second electrode is at least partially positioned after implantation in the host outside of a site affected by cessation or reduction of blood flow.

17 . A system for detecting glucose comprising:
a sensor configured to be inserted within a host, the sensor configured to generate sensor data indicative of a concentration of glucose in the host; and sensor electronics in communication with the sensor, wherein the sensor electronics include at least one processor configured to:
identify a post-implantation loss of sensitivity of the sensor by measuring a plurality of time-varying concentration values of a non-glucose analyte and determine if at least one of the plurality of time-varying concentration values of the non-glucose analyte changes more than a predetermined amount,
release a bio-active agent configured to minimize reduction or cessation of blood flow to a site surrounding sensor implantation based on the identification of the post-implantation loss of sensitivity, and
process the sensor data responsive to the identification of the post-implantation loss of sensitivity.

18 . The system of claim 17 wherein the non-glucose analyte is oxygen.

Assignees

• Dexcom Inc

Inventors

• Bhavaraju Naresh C
• Böhm Sebastian
• Boock Robert
• Rong Daiting
• Simpson Peter C

Classifications

• A61B5/14865

  invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors · CPC title

• A61B5/7221

  Determining signal validity, reliability or quality (preventing, reducing or removing noise induced by motion artefacts A61B5/7207; noise originating from a therapeutic or surgical apparatus A61B5/7217) · CPC title

• A61B2562/04

  Arrangements of multiple sensors of the same type · CPC title

• A61B5/7246

  using correlation, e.g. template matching or determination of similarity · CPC title

• A61B5/14532

  for measuring glucose, e.g. by tissue impedance measurement · CPC title